| Daliresp (roflumilast) / AstraZeneca |
| Completed | N/A | 15 | US | | Creighton University, Takeda | Allergy, Asthma | 01/10 | 01/10 | | |
DACOTA, NCT01285167: Quality of Life in Daxas-treated Patients Older Than 18 Years With Severe Chronic Obstructive Pulmonary Disease (COPD) |
|
|
| Completed | N/A | 3645 | Europe | Daxas | AstraZeneca | Chronic Obstructive Pulmonary Disease | 02/12 | 02/12 | | |
DINO, NCT01285180: Quality of Life in Daxas-treated Patients Older Than 18 Years With Severe COPD |
|
|
| Completed | N/A | 5472 | Europe | Daxas | AstraZeneca | Severe COPD | 08/12 | 08/12 | | |
ATLAS, NCT02187926: Evaluation of Clinical Effectiveness of Roflumilast in Routine Practice, in Chronic Obstructive Pulmonary Disease (COPD) Patients in Greece |
|
|
| Completed | N/A | 2577 | Europe | | AstraZeneca | Chronic Obstructive Pulmonary Disease | 12/13 | 12/13 | | |
NCT01572948: A Placebo-controlled Trial of Daliresp on Chronic Obstructive Pulmonary Disease (COPD) |
|
|
| Completed | N/A | 27 | US | roflumilast, Daliresp, placebo | University of Alabama at Birmingham | COPD | 06/14 | 06/14 | | |
| Completed | N/A | 1950 | Europe, RoW | | AstraZeneca | Chronic Obstructive Pulmonary Disease | 08/16 | 08/16 | | |
NCT02068456: Post Marketing Surveillance of Roflumilast in Korea |
|
|
| Completed | N/A | 1837 | RoW | Roflumilast, Daxas, Daliresp | AstraZeneca | Chronic Obstructive Pulmonary Disease | 04/17 | 04/17 | | |
| Unknown status | N/A | 150 | US | roflumilast, Daliresp, ustekinumab, Stelara | Millennium Magnetic Technologies, LLC | Alzheimer Disease | 09/19 | 09/20 | | |
NCT03381573: Long-term Observational Study of the Safety of Roflumilast |
|
|
| Completed | N/A | 135856 | Europe, US | Roflumilast | AstraZeneca | COPD | 09/22 | 09/22 | | |
ARGO, NCT05426915: Clinical Study for the Effectiveness of Roflumilast Treatment in COPD Greek Patients Based on Standard Clinical Practice. |
|
|
| Recruiting | N/A | 750 | Europe | | Elpen Pharmaceutical Co. Inc. | Copd, COPD Exacerbation | 05/24 | 05/24 | | |
